文献速递肿瘤 PET/CT

稳健影像组学特征预筛未改善局部晚期非小细胞肺癌FDG-PET结局建模

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging.
PubMed 文献 · EJNMMI Res · 2021-08-21

本研究从IIIA/N2或IIIB期非小细胞肺癌患者的治疗前[18F]FDG-PET中提取1404个原发肿瘤影像组学特征,在训练队列(n=79,16中心)和内部验证队列(n=31)中比较稳健特征预筛与全特征建模对12/24个月无事件生存和总生存的预测价值,发现稳健预筛模型预测失败,而无预筛模型对12个月EFS预测良好。

要点

  • 稳健性研究仅识别179个稳定特征(13%),单变量分析无稳健特征显著预测12/24个月EFS及12个月OS。
  • 无稳健预筛的预后模型对12个月EFS训练AUC=0.73、验证AUC=0.74,风险分层在训练和验证队列均显著。
  • 稳健特征预筛模型预测不成功,提示需标准化成像协议。

核心结论

  • 基于标准化多中心数据集的PET影像组学模型可成功建立并验证,对局部晚期NSCLC的EFS预测性能良好。
  • 采用稳健特征预筛的预测模型未成功,表明需要标准化成像协议。

研究设计与样本

  • 从IIIA/N2或IIIB期NSCLC患者治疗前[18F]FDG-PET提取1404个原发肿瘤影像组学特征。
  • 训练队列n=79来自前瞻性瑞士多中心随机III期试验SAKK 16/00(16中心),内部验证队列n=31来自单中心。
  • 开展勾画变异、衰减校正和运动稳健性研究,组内相关系数阈值>0.9。
  • 训练两个12/24个月EFS和OS逻辑回归模型:仅用稳健特征与用全部可用特征,采用五折交叉验证及独立单中心数据集验证,以AUC评估性能。

主要发现

  • 稳健性研究识别179个稳定特征(13%),其中3D vs 4D采集稳定特征占25%,衰减校正占31%,勾画占78%。
  • 单变量分析未发现显著稳健特征预测12/24个月EFS和12个月OS(p值>0.076)。
  • 无稳健预筛的预后模型对12个月EFS训练AUC=0.73、验证AUC=0.74。
  • 基于12个月EFS将患者分为两个风险组,训练队列p值=0.02,验证队列p值=0.03。

关键数值与推荐

  • 稳健特征定义为组内相关系数阈值>0.9。
  • 稳定特征占比:总体13%,3D vs 4D采集25%,衰减校正31%,勾画78%。
  • 单变量分析p值>0.076为无显著稳健特征预测的阈值。
  • 无预筛模型12个月EFS训练AUC=0.73、验证AUC=0.74;风险分层训练p=0.02、验证p=0.03。

临床怎么用

  • 在局部晚期NSCLC中,基于FDG-PET的影像组学模型可不经稳健特征预筛直接预测12个月EFS。
  • 稳健特征预筛未能改善结局建模,临床建模时应优先确保成像协议标准化。

局限性

  • 稳健特征预筛模型预测不成功,提示扫描与采集差异影响特征稳健性。
  • 研究基于特定分期(IIIA/N2或IIIB)NSCLC人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiomics is a promising tool for identifying imaging-based biomarkers. Radiomics-based models are often trained on single-institution datasets; however, multi-centre imaging datasets are preferred for external generalizability owing to the influence of inter-institutional scanning differences and acquisition settings. The study aim was to determine the value of preselection of robust radiomic features in routine clinical positron emission tomography (PET) images to predict clinical outcomes in locally advanced non-small cell lung cancer (NSCLC). METHODS: A total of 1404 primary tumour radiomic features were extracted from pre-treatment [18F]fluorodeoxyglucose (FDG)-PET scans of stage IIIA/N2 or IIIB NSCLC patients using a training cohort (n = 79; prospective Swiss multi-centre randomized phase III trial SAKK 16/00; 16 centres) and an internal validation cohort (n = 31; single centre). Robustness studies investigating delineation variation, attenuation correction and motion were performed (intraclass correlation coefficient threshold > 0.9). Two 12-/24-month event-free survival (EFS) and overall survival (OS) logistic regression models were trained using standardized imaging: (1) with robust features alone and (2) with all available features. Models were then validated using fivefold cross-validation, and validation on a separate single-centre dataset. Model performance was assessed using area under the receiver operating characteristic curve (AUC). RESULTS: Robustness studies identified 179 stable features (13%), with 25% stable features for 3D versus 4D acquisition, 31% for attenuation correction and 78% for delineation. Univariable analysis found no significant robust features predicting 12-/24-month EFS and 12-month OS (p value > 0.076). Prognostic models without robust preselection performed well for 12-month EFS in training (AUC = 0.73) and validation (AUC = 0.74). Patient stratification into two risk groups based on 12-month EFS was significant for training (p value = 0.02) and validation cohorts (p value = 0.03). CONCLUSIONS: A PET-based radiomics model using a standardized, multi-centre dataset to predict EFS in locally advanced NSCLC was successfully established and validated with good performance. Prediction models with robust feature preselection were unsuccessful, indicating the need for a standardized imaging protocol.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Oliveira C, Amstutz F, Vuong D, et al. Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. EJNMMI Res. 2021. PMID: 34417899. doi:10.1186/s13550-021-00809-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。